What is kisspeptin used for?

Kisspeptin is being researched for reproductive medicine applications including treating hypothalamic amenorrhoea, IVF support, and diagnosing reproductive disorders. It is not yet approved for any therapeutic use.

How does kisspeptin differ from GnRH?

Kisspeptin works upstream of GnRH, stimulating GnRH neurons to release their hormone. It may offer more physiological stimulation and potentially fewer side effects than direct GnRH analogues in some contexts.

Can kisspeptin help with fertility?

Research suggests kisspeptin may help women with hypothalamic amenorrhoea (absent periods due to hypothalamic dysfunction) and may have roles in IVF. Clinical trials are ongoing but no approved therapies exist yet.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

Hormonal & Endocrine•Updated 2026-02-01•5 min read

What Is Kisspeptin-10? Benefits, Research & Safety

A decapeptide hormone critical for initiating puberty and regulating reproductive hormone release, with emerging research applications.

Share:X Post LinkedIn

Also known as:

Metastin

KP-10

Kisspeptin 45-54

CLimited human evidenceUK: Unlicensed (UK)WADA: Sport status unclear

UK summary: Not a licensed UK medicine. Reproductive-endocrinology peptide investigated for hypothalamic amenorrhoea, IVF triggers, and diagnostic use. Genuine clinical-research interest with promising trial data; not a wellness product.

Quick Facts

Overview

Kisspeptin-10 (KP-10) is a 10-amino acid peptide derived from the larger kisspeptin-54 (formerly known as metastin), encoded by the KISS1 gene. Kisspeptins are now recognised as master regulators of the reproductive axis, playing a critical role in initiating puberty and maintaining normal reproductive function. Kisspeptins act on the KISS1R receptor (formerly GPR54) located on gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. Activation of this receptor stimulates GnRH release, which in turn triggers the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, ultimately affecting gonadal function. Research into kisspeptin has provided fundamental insights into the regulation of puberty and fertility. Mutations in either KISS1 or KISS1R cause hypogonadotropic hypogonadism (failure to undergo puberty), demonstrating the system's essential role. Kisspeptin-10 is being investigated for potential therapeutic applications in reproductive medicine, including treatment of hypothalamic amenorrhoea, support for IVF protocols, and diagnosis of reproductive disorders. Some clinical studies have been conducted, though no approved medications currently exist. The peptide also has relevance to conditions such as polycystic ovary syndrome (PCOS) and the metabolic-reproductive interface, given kisspeptin's role as an integrator of energy status and reproduction.

Evidence standards summary

Kisspeptin-10 — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

CLimited human evidenceOverall grade against our evidence grading methodology.

Not a licensed UK medicine. Reproductive-endocrinology peptide investigated for hypothalamic amenorrhoea, IVF triggers, and diagnostic use. Genuine clinical-research interest with promising trial data; not a wellness product.

02Human evidence grade

CLimited human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

AStrong human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Not licensed. Research compound under clinical investigation.
EU: Not approved. Clinical trials ongoing at various centres.
Notes: Kisspeptin is actively being researched for therapeutic applications in reproductive medicine. No approved products exist yet. Research is particularly active at Imperial College London and other major centres.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Restores ovulation in any cause of female sub-fertility.
Boosts testosterone in healthy men.
Treats hypoactive sexual desire disorder.
Safe to self-administer at home.

07Common internet claims

Marketed by some private fertility clinics off-label.
Sold by online retailers as a research-only injection.
Promoted in 'hormonal optimisation' stacks alongside testosterone.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Triggers natural ovulation for IVF”	B	Yes	Moderate	Kisspeptin has been studied as an IVF trigger with promising results; it is not a licensed UK fertility medicine and is used in research settings only.
“Restores periods in functional hypothalamic amenorrhoea”	C	Limited	Moderate	Trial data are encouraging for hypothalamic amenorrhoea; not yet a licensed treatment.
“Sexual-arousal enhancer”	D	Limited	High	Some research suggests effects on sexual arousal pathways; this is not a licensed indication and trial data is preliminary.
“Available from research peptide suppliers — safe to self-administer”	E	No	High	Reproductive hormones should be assessed and managed by specialists; self-administration carries serious risk.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

Specialist-supervised use in IVF trials shows good short-term tolerability.
Unsupervised use risks disrupting HPG axis in unpredictable ways.
Injection-site reactions.
Theoretical risk of triggering ovarian hyperstimulation if used outside trial protocols.

11Drug-interaction uncertainty

Moderate

Some interaction data published; check with a prescriber for your specific medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Unlicensed (UK)

Not licensed. Research compound under clinical investigation.

Read the full UK legal guide → Are peptides legal in the UK?

14EU legal position

Not approved. Clinical trials ongoing at various centres.

15What this page cannot tell you

Whether a UK-purchased vial contains kisspeptin-10 at the labelled concentration.
What dose and timing produce safe ovulation triggering outside an IVF setting.
How chronic use would affect endogenous HPG-axis function.
Whether off-label male / HSDD use carries the same safety profile as the research IVF use.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

BModerate human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Imperial College London research is strong but kisspeptin-as-IVF-trigger is not yet in routine NHS practice.
Male and HSDD outcome trials are limited.
Long-term safety beyond a single trigger event is unstudied.
Optimal dose / timing remains research-stage.

19Safer alternatives / established care pathways

Specialist reproductive-medicine referral via NHS or HFEA-licensed private clinic for fertility concerns.
Licensed gonadotrophins and IVF triggers (hCG, GnRH agonist) under specialist supervision.
Endocrinology referral for HPG-axis investigation in suspected hypogonadism.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is Kisspeptin-10 a licensed UK fertility medicine?
Are there UK clinical trials I might be eligible for?
What licensed treatments exist for my fertility / endocrine concern?
If a clinic is offering kisspeptin outside a trial, what's the regulatory framing?

Discovery & History

The kisspeptin story began in 1996 when the KISS1 gene was identified as a metastasis suppressor gene in melanoma cells—hence the original name "metastin." The gene was found at the Hershey Medical Center in Pennsylvania, leading to the playful name "KISS1" (a reference to Hershey's Kisses chocolates). For several years, KISS1/metastin was studied primarily in cancer research. The discovery of its critical role in reproduction came in 2003 when two independent groups discovered that mutations in the KISS1 receptor (GPR54) caused hypogonadotropic hypogonadism—failure to undergo puberty. This discovery fundamentally changed understanding of reproductive neuroendocrinology. Kisspeptin was rapidly established as the key upstream regulator of GnRH release, effectively serving as the "on switch" for puberty and the gatekeeper of reproductive function. Subsequent research revealed that kisspeptin neurons integrate multiple signals—including metabolic status, stress, and day length—to appropriately regulate reproduction. This helps explain why conditions like anorexia nervosa or extreme exercise suppress menstruation. Active clinical research is ongoing into kisspeptin's therapeutic potential, with studies investigating its use in IVF, hypothalamic amenorrhoea, and as a diagnostic tool for reproductive disorders.

Mechanism of Action

Kisspeptin-10 works through a specific receptor to control the reproductive hormone axis: **KISS1R (GPR54) Activation** Kisspeptin-10 binds to and activates KISS1R on hypothalamic GnRH neurons: - Triggers immediate GnRH release - All isoforms of kisspeptin (KP-10, KP-13, KP-14, KP-54) activate the same receptor - KP-10 contains the minimal sequence needed for full receptor activation **GnRH-Gonadotropin Cascade** Activation of GnRH neurons initiates the reproductive cascade: - GnRH release from hypothalamus - Stimulation of LH and FSH release from pituitary - Effects on gonads (testosterone/oestrogen production, gametogenesis) **Pulsatility and Desensitisation** The mode of kisspeptin administration affects responses: - Pulsatile kisspeptin maintains GnRH pulsatility - Continuous kisspeptin administration can cause desensitisation - This has implications for therapeutic applications **Integration of Metabolic Signals** Kisspeptin neurons receive and integrate multiple inputs: - Leptin (energy status) - Stress hormones - Sex steroids (feedback) - Circadian signals - This explains the link between energy status and fertility

Researched Benefits

Based on preclinical and clinical research findings:

1
Potent stimulation of LH and FSH release
2
Potential treatment for hypothalamic amenorrhoea
3
Possible IVF trigger alternative to hCG
4
Diagnostic applications for reproductive disorders
5
Research tool for studying reproductive physiology
6
May offer advantages over GnRH analogues in certain contexts

Claim vs Evidence

How popular claims about Kisspeptin-10 stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Triggers natural ovulation for IVF”	B	Yes	Moderate	Kisspeptin has been studied as an IVF trigger with promising results; it is not a licensed UK fertility medicine and is used in research settings only.
“Restores periods in functional hypothalamic amenorrhoea”	C	Limited	Moderate	Trial data are encouraging for hypothalamic amenorrhoea; not yet a licensed treatment.
“Sexual-arousal enhancer”	D	Limited	High	Some research suggests effects on sexual arousal pathways; this is not a licensed indication and trial data is preliminary.
“Available from research peptide suppliers — safe to self-administer”	E	No	High	Reproductive hormones should be assessed and managed by specialists; self-administration carries serious risk.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Variable depending on research application; 0.3-13 nmol/kg in clinical studies
Frequency	Single dose, pulsatile, or continuous depending on study design
Duration	Variable; acute studies to multi-week protocols
Notes	Kisspeptin-10 is not approved for therapeutic use. Clinical research is ongoing. The mode of administration (pulsatile vs continuous) significantly affects outcomes. All use should be in research settings under appropriate supervision.

Administration Routes

Routes studied in research settings (educational only):

Intravenous infusion (most clinical research)
Subcutaneous injection (some protocols)

Half-Life	Stability
Short; approximately 27.6 minutes for kisspeptin-54, shorter for KP-10	Requires careful handling; lyophilised form for storage

Safety Profile & Known Risks

Commonly Reported Side Effects

Transient hot flushes
Injection site reactions
Headache
Generally well-tolerated in clinical studies

Rare Risks & Concerns

Limited long-term data in humans
Potential for desensitisation with continuous use
Unknown effects of chronic administration

Contraindications

Hormone-sensitive cancers (stimulates sex hormones)
Pregnancy (effects unknown)
Conditions where hormonal stimulation is contraindicated

UK & EU Regulatory Context

🇬🇧 United Kingdom

Not licensed. Research compound under clinical investigation.

🇪🇺 European Union

Not approved. Clinical trials ongoing at various centres.

Kisspeptin is actively being researched for therapeutic applications in reproductive medicine. No approved products exist yet. Research is particularly active at Imperial College London and other major centres.

Clinical Studies Summary

An increase in kisspeptin-54 release occurs with the pubertal increase in luteinizing hormone-releasing hormone-1 release in the stalk-median eminence of female rhesus monkeys in vivo.

Kisspeptin-10 infusion through a microdialysis probe significantly stimulated LHRH-1 release in a dose-dependent manner. Collectively, the results are consistent with the hypothesis that kisspeptin plays a role in puberty.

Endocrinology. 2008View on PubMed

Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.

Kisspeptin-10 boluses potently evoke LH secretion in men, and continuous infusion increases testosterone, LH pulse frequency, and pulse size. Kisspeptin analogues have therapeutic potential as regulators of LH and thus testosterone secretion.

J Clin Endocrinol Metab. 2011View on PubMed

The roles of kisspeptin and neurokinin B in GnRH pulse generation in humans, and their potential clinical application.

These finds indicate that pulsatile secretion and action of kisspeptin on GnRH neurons is not required for the generation of LH (GnRH) pulses in humans. We also report that there is an absence of desensitization in humans exposed to continuous infusion of kisspeptin-10 at receptor-saturating concentrations over 22 h and briefly review GnRH, kisspeptin and NKB analogs and their clinical application.

J Neuroendocrinol. 2022View on PubMed

KISS1 in breast cancer progression and autophagy.

Besides, recent evidence suggests involvement of KISS1 in the mechanisms of tumor angiogenesis, autophagy and apoptosis regulation, suggesting a possible role in both restricting and promoting cancer cell invasion.

Cancer Metastasis Rev. 2019View on PubMed

Role of Kisspeptin and NKB in Puberty in Nonhuman Primates: Sex Differences.

By contrast, during puberty in males, reciprocal pathways are consolidated to a simpler kisspeptin-dominant signaling pathway. Nevertheless, in primates, both kisspeptin and NKB signaling are contributing factors for the pubertal increase in GnRH release, rather than initiating puberty.

Semin Reprod Med. 2019View on PubMed

Kisspeptin as a promising oocyte maturation trigger for in vitro fertilisation in humans.

Also, its safety in patients at high risk of developing ovarian hyperstimulation syndrome is noteworthy. Nevertheless, further studies would be desirable to establish the optimal trigger of egg maturation and to improve the reproductive outcome for women undergoing IVF treatment.

Gynecol Endocrinol. 2017View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 3

Approved product

3 of 3 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp

PHASE1

Status: Withdrawn · Massachusetts General Hospital

Conditions: Metabolic Disease

No results postedNCT05456854

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

PHASE1

Status: Withdrawn · Stephanie B. Seminara, MD

Conditions: Insulin, Glucose, Healthy Volunteers

No results postedNCT04532801

Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men

PHASE3

Status: Completed · 15 participants · Quaid-e-Azam University

Conditions: Sterility, Reproductive

No results postedNCT03315325

Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.

PHASE3

Status: Completed · 30 participants · Ghulam Nabi

Conditions: Reproductive Physiological Phenomena

No results postedNCT03286517

KP-10 and Insulin Secretion in Men

PHASE3

Status: Completed · 14 participants · Quaid-e-Azam University

Conditions: Kisspeptin Action on Insulin in Healthy Normal Men, Kisspeptin Action on Insulin in Obese Diabetic Men

No results postedNCT03771326

Adverse event reports (FDA FAERS)

Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Kisspeptin-10?

Source research-grade Kisspeptin-10 from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Kisspeptin-10

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is Kisspeptin-10 a licensed UK fertility medicine?
Are there UK clinical trials I might be eligible for?
What licensed treatments exist for my fertility / endocrine concern?
If a clinic is offering kisspeptin outside a trial, what's the regulatory framing?

Quick Facts

Overview

01Evidence snapshot

02Human evidence grade

03Preclinical evidence grade

04Regulatory status

05Approved medical uses

06Unapproved / promotional claims

07Common internet claims

08Claim vs evidence

09Safety uncertainty score

10Known adverse signals

11Drug-interaction uncertainty

12Anti-doping status

13UK legal position

14EU legal position

15What this page cannot tell you

16Last reviewed

17Citation quality score

18Research gaps

19Safer alternatives / established care pathways

20Doctor discussion prompts

Questions to ask a qualified clinician

Discovery & History

Mechanism of Action

Researched Benefits

Claim vs Evidence

Theoretical Dosing & Protocols

Administration Routes

Safety Profile & Known Risks

Commonly Reported Side Effects

Rare Risks & Concerns

Contraindications

UK & EU Regulatory Context

🇬🇧 United Kingdom

🇪🇺 European Union

Clinical Studies Summary

An increase in kisspeptin-54 release occurs with the pubertal increase in luteinizing hormone-releasing hormone-1 release in the stalk-median eminence of female rhesus monkeys in vivo.

Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.

The roles of kisspeptin and neurokinin B in GnRH pulse generation in humans, and their potential clinical application.

KISS1 in breast cancer progression and autophagy.

Role of Kisspeptin and NKB in Puberty in Nonhuman Primates: Sex Differences.

Kisspeptin as a promising oocyte maturation trigger for in vitro fertilisation in humans.

Registered Trials & Regulatory Status

Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men

Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.

KP-10 and Insulin Secretion in Men

Adverse event reports (FDA FAERS)

Looking for Kisspeptin-10?

Frequently Asked Questions

What is kisspeptin used for?

How does kisspeptin differ from GnRH?

Can kisspeptin help with fertility?

Questions to ask a qualified clinician about Kisspeptin-10

UK regulatory & safety context

Are peptides legal in the UK?

Unlicensed peptide risks

Related Research Guides

Peptides for Sexual Health

Related Peptides

GHRP-2

Oxytocin

GnRH

Explore More Peptides